Bone Marrow Derived Mesenchymal Stem Cell Augmentation of Rabbit Flexor Tendon Healing

Area of Science:

• Regenerative Medicine
• Orthopedic Surgery
• Biomaterials Science

Background:

• Flexor tendon injuries often result in adhesions and impaired healing.
• Mesenchymal stem cells (MSCs) show potential for tissue regeneration.
• Autologous and allogeneic MSCs may offer different therapeutic benefits.

Purpose of the Study:

• To evaluate the efficacy of mesenchymal stem cell (MSC) implantation in a rabbit flexor tendon repair model.
• To compare the effects of autologous versus allogeneic MSCs on tendon healing.
• To investigate the impact of cell dosage on flexor tendon repair outcomes.

Main Methods:

• Rabbit model of flexor tendon repair with four treatment groups: control, 1 million autologous MSCs, 1 million allogeneic MSCs, and 4 million allogeneic MSCs.
• Animals were evaluated at 3 and 8 weeks post-surgery.
• Assessment included range of motion, collagen I expression, and biomechanical properties.

Main Results:

• A significant increase in range of motion was observed in the high-dose allogeneic MSC group (4 million cells) at 3 weeks compared to controls.
• Enhanced collagen I expression was noted in MSC-treated groups at 3 weeks.
• No significant improvement in biomechanical properties was found in any MSC-treated group.

Conclusions:

• High-dose allogeneic MSC implantation attenuated early adhesions in flexor tendon repair.
• MSC therapy did not improve the ultimate biomechanical strength of repaired tendons.
• Further investigation is warranted to establish the clinical value of MSC therapy for human flexor tendon healing.